Intra-Cellular Therapies(ITCI) - 2024 Q4 - Annual Results

Exhibit 99.1 INTRA-CELLULAR THERAPIES REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in 2023 Full year 2024 CAPLYTA net product sales were $680.5 million, representing year-over-year growth of 47% The U.S. Food and Drug Administration (FDA) accepted for review the lumateperone supplemental New Drug Application (sNDA) submission for adjunctive treatment of major depressive disor ...